Stem Cell Therapy for Type 1 Diabetes Mellitus

Launched by CELLONIS BIOTECHNOLOGY CO. LTD. · Jun 11, 2010

Keywords

ClinConnect Summary

To evaluate the feasibility, safety and efficacy of transplantation using autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells in patients with type 1 diabetes mellitus.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Free will taking part in the study and ability to provide written informed consent.
• • 2. Confirmed diagnosis of type I diabetes for at least 2 years
• • 3. Insulin-dependent.
• • 4. Age 18-50 years, Male/Female.
• • 5. FBG≥7.0 mmol/L, and HbAc1≥7％.
• • 6. Not pregnant or nursing.
• • 7. Negative pregnancy test.
• • 8. Fertile patients will use effective contraception.
• Exclusion Criteria:
• • 1. Presence of acute diabetic complications in the acute stage as recent myocardial infarction, recent cerebral vascular accident (CVA) or acute renal failure.
• • 2. Severe concurrent medical condition (e.g. lung disease, or hematopoietic dysfunction, or liver dysfunction).
• • 3. Active infection requiring treatment.
• • 4. Known immunosuppressive disease, e.g. HIV infection, or hepatitis B or C infection.